Clinical Trials
17 trialsNCT04485013 2026-02-18
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Phase 1 Recruiting
NCT03806309 2025-07-25
TEDOPAM
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Active not recruiting
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT05087992 2025-02-19
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
Boehringer Ingelheim
Phase 1 Completed
NCT04247256 2022-03-02
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI
Scandion Oncology A/S
Phase 1/2 Unknown
NCT02181556 2021-06-07
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT02015923 2021-03-16
CCRe-IV
Hospital Universitari de Bellvitge
Phase 4 Terminated
NCT02726334 2019-01-16
A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.
Bionomics Limited
Phase 1 Terminated
NCT01888978 2018-04-09
Molecularly Tailored Therapy for Pancreas Cancer
Georgetown University
Phase 2 Completed
NCT02045030 2016-11-16
Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
CR-CSSS Champlain-Charles-Le Moyne
Phase 2 Terminated
NCT00813605 2016-10-27
QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
NantCell, Inc.
Phase 2 Completed
NCT00411450 2016-02-15
PRECEPT
Amgen
Phase 2 Completed
NCT00752570 2015-09-02
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
Amgen
Phase 2 Completed
NCT00719199 2013-10-22
Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer
EMD Serono
Phase 1 Terminated
NCT01543412 2012-03-05
SLAP
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Phase 2 Completed
NCT00313872 2012-01-12
Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer
Samsung Medical Center
Phase 3 Completed
NCT00374036 2011-10-12
Metastatic Gastric Cancer FFCD 03-07
University Hospital, Toulouse
Phase 3 Completed